+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

NovoCure Ltd (NVCR) - Financial and Strategic SWOT Analysis Review

  • ID: 4278898
  • SWOT Analysis
  • April 2020
  • 54 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Flowonix Medical Inc
  • Hologic Inc
  • MagForce AG
  • MDxHealth SA
  • Monteris Medical Inc
  • SonALASense Inc
  • MORE
NovoCure Ltd (NVCR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

NovoCure Ltd (NovoCure) develops and commercializes novel delivery systems for the treatment of cancers of brain, abdomen, and torso. Its proprietary Tumor Treating Fields (TTF) technology platform uses electric fields tuned to specific frequencies for disrupting the division solid tumor cancer cells. The company markets TTF-based delivery systems: NovoTTF-100L for the treatment of malignant pleural mesothelioma; and Optune for the treatment of glioblastoma. Both of its marketed products are indicated in combination with standard chemotherapies. NovoCure is also advancing product development and clinical programs intended to improve the survival of patients with brain metastases, pancreatic cancer, ovarian cancer, liver cancer, gastric cancer, and non-small cell lung cancer. It has subsidiaries in Europe, the Middle East, Asia, and North America. NovoCure is headquartered in Saint Helier, Jersey, the UK.

NovoCure Ltd Key Recent Developments

Mar 31,2020: Novocure Announces Brand Name for NovoTTF-100L Mesothelioma Treatment
Feb 27,2020: Novocure reports fourth quarter and full year 2019 financial results and provides company update
Jan 13,2020: Novocure announces fourth quarter and full year 2019 preliminary net revenues and provides company update
Dec 02,2019: Novocure and the AACR announce 2nd Annual AACR-Novocure Grants for tumor treating fields research program
Nov 20,2019: Novocure announces 43 presentations on tumor treating fields at 24th Annual Meeting of the Society for Neuro-Oncology

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Flowonix Medical Inc
  • Hologic Inc
  • MagForce AG
  • MDxHealth SA
  • Monteris Medical Inc
  • SonALASense Inc
  • MORE
Section 1 - About the Company
  • NovoCure Ltd - Key Facts
  • NovoCure Ltd - Key Employees
  • NovoCure Ltd - Key Employee Biographies
  • NovoCure Ltd - Major Products and Services
  • NovoCure Ltd - History
  • NovoCure Ltd - Company Statement
  • NovoCure Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 – Company Analysis
  • Company Overview
  • NovoCure Ltd - Business Description
  • Geographical Segment: EMEA
  • Performance
  • Geographical Segment: Greater China
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • NovoCure Ltd - Corporate Strategy
  • NovoCure Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • NovoCure Ltd - Strengths
  • NovoCure Ltd - Weaknesses
  • NovoCure Ltd - Opportunities
  • NovoCure Ltd - Threats
  • NovoCure Ltd - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
  • Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • NovoCure Ltd, Medical Equipment, Deals By Year, 2014 to YTD 2020
  • NovoCure Ltd, Medical Equipment, Deals By Type, 2014 to YTD 2020
  • NovoCure Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • Feb 27, 2020: Novocure reports fourth quarter and full year 2019 financial results and provides company update
  • Jan 13, 2020: Novocure announces fourth quarter and full year 2019 preliminary net revenues and provides company update
  • Dec 02, 2019: Novocure and the AACR announce 2nd Annual AACR-Novocure Grants for tumor treating fields research program
  • Nov 20, 2019: Novocure announces 43 presentations on tumor treating fields at 24th Annual Meeting of the Society for Neuro-Oncology
  • Oct 31, 2019: Novocure reports third quarter 2019 financial results and provides company update
  • May 02, 2019: Novocure reports first quarter 2019 financial results and provides company update
  • Apr 03, 2019: Inaugural AACR-Novocure Tumor Treating Fields research grant recipients announced at AACR annual meeting 2019
  • Mar 21, 2019: Novocure’s Chief Science Officer retires after 17 years of service
  • Mar 21, 2019: Novocure announces 48 presentations and a symposium session on Tumor Treating Fields at the American Association for Cancer Research annual meeting 2019
  • Feb 28, 2019: Novocure reports fourth quarter and full year 2018 financial results and provides company update
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • NovoCure Ltd, Key Facts
  • NovoCure Ltd, Key Employees
  • NovoCure Ltd, Key Employee Biographies
  • NovoCure Ltd, Major Products and Services
  • NovoCure Ltd, History
  • NovoCure Ltd, Subsidiaries
  • NovoCure Ltd, Key Competitors
  • NovoCure Ltd, Ratios based on current share price
  • NovoCure Ltd, Annual Ratios
  • NovoCure Ltd, Annual Ratios (Cont...1)
  • NovoCure Ltd, Interim Ratios
  • NovoCure Ltd, Medical Equipment, Deals By Year, 2014 to YTD 2020
  • NovoCure Ltd, Medical Equipment, Deals By Type, 2014 to YTD 2020
  • NovoCure Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • NovoCure Ltd, Performance Chart (2015 - 2019)
  • NovoCure Ltd, Ratio Charts
  • NovoCure Ltd, Medical Equipment, Deals By Year, 2014 to YTD 2020
  • NovoCure Ltd, Medical Equipment, Deals by Type, 2014 to YTD 2020
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Hologic Inc
  • Monteris Medical Inc
  • Advanz Pharmaceutical Corp Ltd
  • SonALASense Inc
  • Flowonix Medical Inc
  • MagForce AG
  • MDxHealth SA
Note: Product cover images may vary from those shown
Adroll
adroll